These data, along with the observation that in MDS, Ezh2 loss facilitates disease occurrence but retards progression to AML (Sashida et al., 2014), provide some reassurances that targeting EZH2 is a safe strategy in established disease. Here, EZH2 is linked to myelodysplastic syndrome.